ABT-450 Shows Promising Results for Hepatitis C Patients
Trial data analysis shows Enanta’s hepatitis C drug is effective
November 4, 2013
By Don Seiffert
BioFlash Editor- Boston Business Journal
Enanta Pharmaceuticals’ partner on a potential drug for hepatitis C presented some promising early results from a mid-stage study of the drug over the weekend.
The Watertown biotech has developed a lead drug, a so-called protease inhibitor named ABT-450, which is part of a hepatitis C drug being tested by Abbott Laboratories. The once-a-day, all-oral drug regimen is notable in that it doesn’t contain interferon, which has been used in previous treatments for hepatitis C but causes flu-like side effects. Several companies are in the late stages of developing interferon-free drugs to treat the infectious liver disease that affects up to 200 million people worldwide. Abbott gave results of a Phase 2b trial of the drug on Sunday at the annual meeting of the American Association for the Study of Liver Diseases in Washington.
Continue reading this entire article: